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OBJECTIVE—White adipose tissue is a critical regulator of
whole-body glucose metabolism. Preadipocyte factor-1 (Pref-1)
is a secreted protein that inhibits adipocyte differentiation, both
in vitro and in vivo. In this study, we have investigated the effects
of Pref-1 overexpression on whole-body glucose homeostasis
and its contribution to the development of insulin resistance.
RESEARCH DESIGN AND METHODS—To gain insight into
the role of Pref-1 on the onset of insulin resistance and type 2
diabetes, we measured body composition and whole-body insu-
lin-stimulated glucose metabolism during a hyperinsulinemic-
euglycemic clamp in Pref-1 transgenic and wild-type control mice
fed a high-fat diet.
RESULTS—Mice overexpressing Pref-1 were resistant to high-
fat diet–induced obesity, as reﬂected by a marked reduction in
adipose tissue mass. However, Pref-1–overexpressing mice were
severely insulin resistant, mainly because of a reduction in
insulin-stimulated glucose uptake in skeletal muscle and adipose
tissue. The aggravated insulin resistance was associated with
impaired insulin signaling and increased diacylglycerol content
in skeletal muscle.
CONCLUSIONS—Mice overexpressing Pref-1 are insulin resis-
tant despite being protected from diet-induced obesity and may
provide a new rodent model for the study of lipodystrophic
disorders. Diabetes 57:3258–3266, 2008
T
he prevalence of type 2 diabetes is rapidly in-
creasing worldwide, and it has been predicted
that 366 million people will be affected by the
year 2030 (1). Although the primary cause of
type 2 diabetes is not well deﬁned, it is believed that
insulin resistance plays a key role in the development of
the disease (2). The mechanisms that trigger insulin resis-
tance remain poorly understood, but evidence points to
alterations in adipose tissue function and a concomitant
ectopic lipid accumulation in muscle and liver as one of
the principal underlying causes.
White adipose tissue (WAT) serves as the main energy
storage depot of the organism. Energy excess stored in the
form of triglycerides is released in periods of scarcity to
supply the energy needs of other tissues. However, adi-
pose tissue also functions as an active endocrine organ by
secreting a variety of biologically active molecules such as
leptin, adiponectin, adipocyte-speciﬁc secretory factor/
resistin, tumor necrosis factor-, interleukin (IL)-6, and
plasma activator inhibitor (rev. in 3 and 4). These adipo-
kines regulate multiple and crucial aspects of the organ-
ism’s physiology, including appetite, energy metabolism,
immune function, and reproduction. Hence, adipose tissue
is now recognized as a key player in the regulation of
energy balance and glucose homeostasis (5). Indeed, al-
terations in the capacity of adipose tissue to store triglyc-
erides or to synthesize/secrete adipokines have been
linked to the appearance of metabolic disease, particularly
insulin resistance and type 2 diabetes (6).
Lipodystrophies, a family of congenital or acquired
disorders characterized by total or partial loss of adipose
mass (rev. in 7), represent one of the best paradigms of
adipose tissue dysfunction. Patients affected by lipodys-
trophy exhibit metabolic complications that include insu-
lin resistance, hyperlipidemia, or diabetes. The pathogenic
basis of most of the lipodystrophies remain still unknown,
and only mutations in a few genes, such as lamin A/C (8),
AGPAT2 (9), seipin (10), or peroxisome proliferator–
activated receptor (PPAR)- (11), have been identiﬁed as a
cause of congenital lipodystrophies. These genes regulate
different aspects of adipose cell biology, particularly me-
tabolism, differentiation, and survival of adipocytes,
underscoring that terminal maturation and proper func-
tionality of adipocytes are essential requirements for ap-
propriate whole-body lipid and glucose homeostasis.
The mechanisms that control adipocyte differentiation
are complex. However, several critical transcriptional
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differentiation have been identiﬁed (rev. in 12 and 13).
Among them, our laboratory identiﬁed preadipocyte
factor-1 (Pref-1) (14) as an inhibitor of adipocyte differen-
tiation, both in vitro and in vivo (rev. in 4). Pref-1 is
synthesized as a transmembrane protein whose epidermal
growth factor repeat-containing ectodomain is cleaved by
tumor necrosis factor-–converting enzyme to release a
biologically active 50-kDa soluble form (15). Soluble Pref-1
functions in a paracrine/endocrine manner to prevent
preadipocyte differentiation through MEK/ERK activation
(16,17). Mouse models of loss or gain of function have
unequivocally demonstrated the important role of Pref-1 in
adipogenesis. Mice lacking Pref-1 show growth retardation
and skeletal abnormalities as well as increased adiposity
when fed a high-fat diet (18), supporting the role of Pref-1
on the regulation of adipocyte differentiation. Accordingly,
young adult mice that overexpress soluble Pref-1 exhibited
a marked reduction in WAT mass as a result of impaired
adipocyte differentiation (19). Interestingly, these mice
also showed skeletal malformations, impaired whole-body
insulin sensitivity, and reduced glucose tolerance. These
reports suggest that alterations in circulating Pref-1 levels
can affect whole-body glucose homeostasis. However, the
effect of Pref-1 on glucose homeostasis, particularly in
individual tissues, or the underlying mechanisms of such
metabolic alterations have not been explored.
Here, we examined the effects of Pref-1 overexpression
on insulin action and glucose and lipid metabolism in mice
that have been chronically fed a high-fat diet. We found
that mice overexpressing Pref-1 were insulin resistant
despite a decrease in fat mass. Therefore, Pref-1 trans-
genic mice may provide a new rodent model of partial
lipodystrophy.
RESEARCH DESIGN AND METHODS
Animals. Generation of transgenic mice (Tg) overexpressing the Pref-1/hFc
fusion protein driven by the adipose-speciﬁc aP2 promoter has been previ-
ously described (19). Wild-type (Wt) and transgenic littermates were fed a
high-fat diet (45% kcal fat, 35% kcal carbohydrate, 20% kcal protein) (Research
Diets, NB, NJ) ad libitum for a period of 17 weeks after weaning. Food intake
was measured every 2 days over a 10-day period in 15-week-old male mice. All
procedures involving animals were conducted in accordance with the institu-
tional animal use and care guidelines of the University of California–Berkeley
and the Yale University School of Medicine.
Body composition. Fat and lean body mass was assessed by
1H magnetic
resonance spectroscopy (Bruker BioSpin, Billerica, MA). The mass of major
adipose depots (gonadal, inguinal, and retroperitoneal depots) was directly
measured by weighing the tissues after dissection.
Adipose tissue histology. Inguinal WAT from 20-week-old Pref-1 Tg mice
and Wt littermates was isolated and ﬁxed overnight in Bouin’s solution. After
dehydration, the tissue was embedded in parafﬁn for subsequent sectioning.
The 8-m sections were stained with hematoxylin-eosin.
Serum metabolites. Blood from Pref-1 Tg mice and Wt littermates random-
fed or fasted for 5 h was collected from tail and centrifuged at 3,000 rpm for
5 min to obtain serum. Triglyceride levels were measured with the Inﬁnity
triglyceride reagent (Sigma, St. Louis, MO). Free fatty acids were determined
with the NEFA-C kit (Wako, Richmond, VA). Circulating insulin and leptin
levels were measured using a rat insulin and mouse leptin enzyme-linked
immunosorbent assay (ELISA) kit (Crystal Chem, Downers Grove, IL),
respectively. For adiponectin, a rat/mouse ELISA kit (B-Bridge, Sunnyvale,
CA) was used. Blood glucose was measured with a blood glucose meter
(AccuCheck; Roche, Indianapolis, IN).
Glucose tolerance test. A glucose tolerance test was performed on 12-h
fasted mice. Blood glucose was measured at 0, 30, 60, 90, and 120 min after an
intraperitoneal injection of glucose (1 g/kg body wt).
Hyperinsulinemic-euglycemic clamp study. Seven days before the hyper-
insulinemic-euglycemic clamp studies, indwelling catheters were placed into
the right internal jugular vein. After an overnight fast, [3-
3H]glucose (HPLC
puriﬁed; Perkin Elmer, Boston, MA) was infused at a rate of 0.05 Ci/min for
2 h to assess the basal glucose turnover. After the basal period, a hyperinsu-
linemic-euglycemic clamp was conducted for 120 min with a primed/contin-
uous infusion of human insulin (105 pmol/kg prime, 15 pmol  kg
1  min
1
infusion) (Novo Nordisk, Princeton, NJ). Blood samples (10 l) were collected
at 10- to 20-min intervals for the immediate measurement of plasma glucose,
and 20% dextrose was infused at variable rates to maintain plasma glucose at
basal concentrations (6.7 mmol/l). To estimate insulin-stimulated whole-
body glucose ﬂuxes, [3-
3H]glucose was infused at a rate of 0.1 Ci/min
throughout the clamps, and 2-deoxy-D-[1-
14C]glucose (Perkin Elmer, Boston,
MA) was injected as a bolus 75 min into the clamp to estimate the rate of
insulin-stimulated tissue glucose uptake as previously described (20). Blood
samples (10 l) for the measurement of plasma
3H and
14C activities were
taken at the end of the basal period and during the last 45 min of the clamp.
At the end of the clamp, mice were killed, and tissues were removed for
biochemical measurements.
Analysis of insulin signaling. After an overnight fast, Wt and Pref-1 Tg mice
were intraperitoneally injected with saline or 0.85 units/kg insulin and killed
10 min after. Lysates from WAT, liver, and skeletal muscle were obtained in
homogenization buffer (150 mmol/l NaCl, 1% Triton X-100, 0.5% sodium
deoxycholate, 0.1% SDS, 10 mmol/l Tris, pH 7.4) containing a protease and
phosphatase inhibitor cocktail (Sigma). Protein (30–60 g) was subjected to
SDS-PAGE and immunoblotted with speciﬁc antibodies for total Akt or Akt
phosphorylated at residue Ser473 (Cell Signaling, Danvers, MA). For insulin
receptor substrate (IRS) phosphorylation, lysates (1 mg protein) were ﬁrst
immunoprecipitated with speciﬁc antibodies against IRS-1 or IRS-2 (Millipore,
Billerica, MA). Immunoprecipitates were then subjected to SDS-PAGE and
blotted with 4G10 antibody (Millipore) that detects phosphorylated tyrosine
residues or antibodies that detect total IRS-1 or IRS-2.
Akt activity. Tissue lysates (500 g protein) were subjected to immunopre-
cipitation for4ha t4 ° Cwith 5 l of a polyclonal Akt antibody (Upstate
Biotechnology), coupled to protein A-sepharose beads. The immune complex
was washed, and Akt activity was determined as described (21).
Lipid metabolites. Tissue triglycerides were extracted using the method of
Bligh and Dyer (22), and content was measured using a DCL Triglyceride
Reagent (Diagnostic Chemicals, Oxford, CT). Fatty acyl-CoA, diacylglycerol,
and ceramide extraction and measurement by liquid chromatography/tandem
mass spectrometry have been described previously (23).
Gene expression. RNA was isolated from skeletal muscle, WAT, and liver,
and cDNAs were synthesized with SuperScript II reverse transcriptase (In-
vitrogen, Carlsbad, CA) and oligo dT. Gene expression was assessed by
real-time quantitative PCR using speciﬁc primers and TaqMan probes for fatty
acid transport protein-1, -2, -4, and -5 and CD36 (Applied Biosystems).
Quantiﬁcation was performed by the CT threshold cycle method, and
relative gene expression was normalized to GAPDH levels.
Statistical analysis. Results are expressed as means  SE. Statistical
signiﬁcance of differences between experimental groups was assessed using
the unpaired Student’s t test.
RESULTS
Pref-1 overexpressing mice are resistant to diet-
induced obesity. We recently reported that overexpres-
sion of a Pref-1/hFc fusion protein in mice impaired
adipocyte differentiation (19). Interestingly, these mice
exhibited a mild degree of glucose intolerance and insulin
resistance at young age (10 weeks old). To further
investigate the effects of Pref-1 overexpression on tissue-
speciﬁc insulin sensitivity, we carried out comparative
studies on Pref-1 Tg mice and Wt littermates fed a high-fat
diet for 17 weeks. High-fat diets are known to induce
obesity and to promote insulin resistance and diabetes in
mice and humans, particularly if individuals are subject to
such diets for a long period of time. At weaning, Pref-1
transgenic male mice weighed slightly less than Wt litter-
mates (Wt  9.5  0.5 g, n  17, vs. Tg  8.4  0.5 g, n 
15; P  0.074) (Fig. 1A). After 17 weeks of high-fat diet
feeding, Wt mice became evidently obese, exhibiting an
average of 8 g in body weight above Pref-1 transgenic
mice, which remained considerably leaner (Wt  43.1 
1.1 g, n  17, vs. Tg  34.8  1.3 g, n  15; P 	 0.01).
Similarly, female transgenic mice were also resistant to
diet-induced obesity (Wt  34.2  1.0 g, n  10, vs. Tg 
28.5  1.5 g, n  10; P 	 0.01) (Fig. 1B). The resistance to
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food intake (Wt  0.420  0.04 kcal  g
1  day
1, n  6, vs.
Tg  0.417  0.03 kcal  g
1  day
1, n  7).
Compared with Wt, Pref-1 Tg mice exhibited a signiﬁ-
cant reduction in the mass of the major WAT depots (Fig.
2A), such as gonadal, inguinal, and renal fat. The inter-
scapular brown adipose tissue was also signiﬁcantly de-
creased. The reduction in adipose tissue mass was
accountable for most of the decrease observed in body
weight, since
1H magnetic resonance spectroscopy re-
vealed no differences in lean mass between Wt and Pref-1
Tg mice (Fig. 2B). Fat depots of Pref-1 transgenic mice
appeared normal by gross morphological examination,
although adipocytes were signiﬁcantly smaller than those
of Wt mice (Fig. 2C). In addition, we have previously
shown that expression levels for adipocyte markers in-
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, C/EBP, and FAS are lower in adipose
tissue of Pref-1 transgenic mice, indicating impairment of
adipocyte differentiation (19). The reduction in adipose
tissue mass and adipocyte size in Pref-1 transgenic mice
was accompanied by an increase in the circulating levels
of free fatty acids and triglycerides, in both fasted and fed
states (Table 1), reﬂecting the fact that Pref-1 transgenic
mice have reduced capacity to store triglycerides in adi-
pose tissue.
Dysregulated glucose homeostasis in Pref-1 trans-
genic mice. The inability of adipocytes to properly store
fat is frequently linked to alterations in glucose homeosta-
sis and development of insulin resistance. Although fasting
plasma glucose levels were similar in Pref-1 Tg and Wt
mice (Table 1), the glucose tolerance test showed that
transgenic mice have an impaired capacity to clear glucose
from circulation compared with Wt mice (Fig. 3A). To
investigate the mechanisms of glucose intolerance, a 2-h
hyperinsulinemic-euglycemic clamp assay was conducted
on awake Wt and Pref-1 transgenic littermates. During the
clamp, plasma insulin level was increased to 330 pmol
and glucose levels were maintained at 120 mg/dl by
variable infusion of glucose. The glucose infusion rate
necessary to maintain euglycemia in Pref-1 Tg mice was
50% lower than in Wt mice, indicating that insulin-stimu-
lated glucose uptake and metabolism was severely blunted
in transgenic mice (Fig. 3B). This could be attributed to a
40% decrease in insulin-stimulated whole-body glucose
uptake in Pref-1 transgenic mice (Fig. 4A). Because he-
patic glucose production (HGP) was similar in Pref-1 Tg
and Wt mice during the clamp as well as in basal condi-
tions, the inability of insulin to suppress HGP during the
clamp in either Wt or Pref-1 Tg mice suggests that both
experimental groups of mice developed severe but similar
hepatic insulin resistance (Fig. 4B). Supporting a similar
HGP, no differences in the expression of key gluconeo-
genic genes Pepck and G6pc3 between Pref-1 transgenic
mice and wild-type littermates were found (data not
shown). On the other hand, consistent with the differences
observed in whole-body glucose uptake between Wt and
Pref-1 Tg mice, insulin-stimulated glucose uptake was
signiﬁcantly reduced in skeletal muscle and WAT of Pref-1
transgenic mice compared with Wt mice (Fig. 4C and D).
Impaired insulin signaling and increased lipid metab-
olites in skeletal muscle of Pref-1 transgenic mice.
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TABLE 1
Serum parameters in fed and 5-h fasted Pref-1 Tg and Wt littermates
Fed Fasted
Wt Pref-1 Tg Wt Pref-1 Tg
Glucose (mg/dl) ND ND 202  11 214  7
FFA (mEq/l) 0.406  0.03 0.560  0.03† 0.710  0.08 0.950  0.08 (P  0.06)
Triglycerides (mg/dl) 54.9  3.7 64.4  7.7 73.5  7 90.2  8.9
Insulin (pg/ml) 5,010  1,041 3,721  819 3,734  525 3,107  554
Adiponectin (g/ml) 24.0  2.7 10.5  0.8† 27.0  3.1 10.1  1.0†
Leptin (ng/ml) 28.0  2.4 5.8  0.9† ND ND
†P 	 0.01, n  6–7. ND, not determined.
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tissues relies on the proper activation of the insulin-
signaling pathway and the correct elicitation of responses
by molecular targets that eventually lead to glucose trans-
port and metabolism. To investigate whether the exacer-
bated insulin resistance present in Pref-1 transgenic mice
is due to defects in insulin signaling, we analyzed the
insulin-stimulated IRS and Akt phosphorylation in a vari-
ety of insulin-sensitive tissues (Fig. 5A and B). Insulin
administration, although at a reduced degree, similarly
increased phosphorylation of IRS-2 and Akt in liver of Wt
and Tg mice, indicating a comparable degree of hepatic
insulin sensitivity. In WAT, insulin-stimulated phosphory-
lation of IRS-1 and IRS-2, as well as Akt, was 50% lower
in Pref-1 Tg mice compared with Wt littermates. More
signiﬁcantly, phosphorylation of IRS-1 and Akt upon injec-
tion of insulin was severely blunted by 80% in skeletal
muscle of Pref-1 Tg mice compared with Wt mice (Fig. 5A
and B). Consistent with these observations, a 40% reduc-
tion in Akt activity was observed in gastrocnemius muscle
of Pref-1 Tg mice compared with Wt mice (Fig. 5C).
Similarly, Akt activity in WAT tended to be 40% lower in Tg
mice. On the other hand, there was no difference in liver
Akt activity in Pref-1 Tg and Wt mice (Fig. 5C). Together,
these results demonstrate that, in Pref-1 Tg mice, insulin
action in WAT and skeletal muscle, the latter being the
major contributor to glucose utilization in the organism, is
strongly impaired.
Evidence suggests that increased lipid accumulation in
nonadipose tissues plays a major role in the development
of insulin resistance associated with obesity and lipodys-
trophy. As shown in Table 1, circulating free fatty acid and
triglyceride levels were higher in Pref-1 transgenic mice,
presumably due to the signiﬁcant reduction in lipid storage
capacity of adipose tissue in these mice. To better under-
stand how the metabolic alterations observed in mice
overexpressing Pref-1 can inhibit insulin signaling and
induce insulin resistance, we analyzed lipid metabolites
content in liver and gastrocnemius muscle of Wt and
Pref-1 transgenic mice. In liver, no signiﬁcant difference in
diacylglycerols (DAG) or fatty acyl-CoAs were found (Fig.
6A), although triacylglycerols and ceramides content was
somewhat reduced (25 and 17%, respectively). In skeletal
muscle, we did not observe any signiﬁcant difference in
triacylglycerol, fatty acyl-CoA, or ceramide content (Fig.
6B) between Wt and Pref-1Tg mice. However, we detected
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of Pref-1 transgenic mice (Fig. 6C). Elevated DAG level in
skeletal muscle has previously been shown to cause
insulin resistance after lipid infusion or fat feeding in
rodents (24–26) as well as humans (27). This suggests that
the increased levels of DAG observed in the skeletal
muscle of Pref-1 transgenic mice could be a contributing
factor for the aggravated insulin resistance associated
with the lipodystrophy present in Pref-1 transgenic mice.
We next examined whether changes in the expression of
proteins involved in ﬂux of fatty acids into the cell,
including FATPs and CD36, contribute to lipid accumula-
tion in tissues of Pref-1 Tg mice. Interestingly, we found a
fourfold increase in CD36 expression in muscle, but not in
liver, whereas no difference was observed in the expres-
sion of FATP family members known to be expressed in
each of these tissues (Fig. 7A and B). In addition, a
substantial decrease in FATP1 and CD36 mRNA was found
in WAT of Pref-1 Tg mice (Fig. 7C), probably due to the
impairment in adipocyte differentiation and lipid accumu-
lation observed in Pref-1 Tg mice. These results suggest
that higher CD36 expression in muscle of Pref-1 Tg mice,
together with increased lipid availability, may contribute
to the preferential lipid, namely DAG, accumulation ob-
served in the skeletal muscle of Pref-1 Tg mice.
DISCUSSION
In this study, we show that high levels of circulating Pref-1
prevent the body weight gain and adipose tissue accumu-
lation that are normally associated with high-fat diets.
However, similar to other models of lipodystrophy, the
resistance to diet-induced obesity exhibited by Pref-1
transgenic mice did not prevent the deleterious effects
associated with feeding of a high-fat diet, such as hyper-
lipidemia and insulin resistance. Indeed, compared with
Wt littermates, Pref-1 transgenic mice showed an aggra-
vated degree of whole-body insulin resistance with higher
circulating lipid levels. A generalized decrease in adipose
tissue mass together with insulin resistance are deﬁning
traits of lipodystrophy (28). In this sense, Pref-1 transgenic
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lipodystrophy.
It is evident that chronic feeding of a high-fat diet
promoted development of glucose intolerance and insulin
resistance in both Wt and Pref-1 transgenic animals. This
is illustrated, for instance, by the very low overall glucose
infusion rate required to maintain euglycemia during hy-
perinsulinemic-euglycemic clamp in Wt and Pref-1 trans-
genic mice fed a high-fat diet, compared with Wt mice fed
a standard chow diet (10% kcal fat) (data not shown).
Indeed, in mice fed a high-fat diet, glucose infusion rate
oscillated between 12.1 and 5.4 mg  kg
1  min
1 in Wt and
Pref-1 Tg mice, respectively (Fig. 3B), whereas the glucose
infusion rate required for maintaining euglycemia in a
cohort of Wt mice fed a normal chow diet for the same
period was approximately three- to sixfold higher (data
not shown). In this sense, the lack of effect of insulin in
inhibiting hepatic glucose production in both Wt and
Pref-1 Tg mice indicates the presence of severe hepatic
insulin resistance in both groups. This is supported by a
weak phosphorylation of hepatic IRS-2 and Akt upon
insulin stimulation and similar Akt activity in liver of both
groups, compared with those observed in other tissues.
Also, the similar degree of activation of the insulin-
signaling pathway in liver of Wt and Tg mice, together
with similar levels of gluconeogenic gene expression in
fed Wt and Tg mice, suggests a comparable degree of
hepatic insulin resistance with a minor contribution of
liver to the differential whole-body insulin sensitivity ex-
hibited by Pref-1 Tg mice. On the other hand, overexpres-
sion of Pref-1 clearly worsens insulin sensitivity in skeletal
muscle, which is considered to be the primary tissue for
insulin-mediated glucose disposal, as well as in adipose
tissue, as demonstrated by a decrease in glucose uptake,
decreased insulin-stimulated IRS and Akt phosphoryla-
tion, and decreased Akt activity. Thus, the differential
degree of insulin resistance in these two insulin-sensitive
tissues of Pref-1 transgenic mice could account for the
observed impairment in whole-body glucose tolerance and
insulin sensitivity in Pref-1 transgenic mice compared with
Wt mice when fed a high-fat diet.
Alterations in adipocyte functions, such as the capacity
to store lipids and to secrete adipokines, have been proven
to have major repercussions in the ability of the organism to
regulate substrate ﬂuxes in tissues and undoubtedly have
impacts on the onset of insulin resistance. Ectopic accu-
mulation of lipids in insulin-sensitive tissues other than
adipose tissue is considered a major cause of the devel-
opment of insulin resistance (2). There is a strong corre-
lation between intramyocellular triglyceride accumulation
and insulin resistance (29,30). However, recent studies
have shown that lipid metabolism intermediates other
than triglycerides, including diacylglycerols (26,27,31),
fatty acyl-CoAs (24,32), and ceramides (33,34), could be
directly responsible for the inhibition of insulin signaling
in the insulin-resistant state. In this regard, compared with
Wt mice, Pref-1 transgenic mice show a signiﬁcant accu-
mulation of diacylglycerols, but not fatty acyl-CoAs, tria-
cylglycerols, or ceramides, in gastrocnemius muscle,
identifying DAG as a potential candidate for the inhibition
of insulin signaling in muscle of Pref-1 Tg mice. The
mechanisms by which mice overexpressing Pref-1 accu-
mulate DAG preferentially in muscle but not in other
insulin-sensitive tissues are still unclear, although the high
expression of the fatty acid transporter CD36 in muscle
could be a factor contributing to lipid accumulation and
insulin resistance in this tissue (35,36). Nevertheless, a
causative relationship between increased DAG accumula-
tion and the development of insulin resistance in muscle of
Pref-1 Tg mice cannot be unequivocally established, and
other possible factors may need to be taken into account.
For instance, the inability of adipocytes from Pref-1 Tg
mice to secrete adequate levels of insulin-sensitizing adi-
pokines, such as leptin and adiponectin, could also con-
tribute to the insulin resistance observed in Pref-1
lipodystrophic mice. In this regard, future experiments of
leptin and/or adiponectin replacement are needed to elu-
cidate the precise role that alteration in leptin/adiponectin
secretion plays in the development of insulin resistance in
Pref-1 Tg mice. In addition, we have observed an increase
in the expression of inﬂammatory cytokines, such as IL-6
and IL-1 but not tumor necrosis factor-, in WAT of
Pref-1 Tg mice, although such an increase does not seem
to be accompanied by macrophage inﬁltration (assessed
by expression of F4/80) (Supplemental Fig. 1, available in
an online appendix at http://dx.doi.org/10.2337/db07-1739).
Hyperlipidemia is often associated with the activation of
inﬂammatory pathways and the appearance of insulin
resistance (rev. in 37). Therefore, besides ectopic lipid
accumulation or decreased endocrine function, a contri-
bution of inﬂammatory pathways to the insulin resistance
of Pref-1 Tg mice cannot be excluded.
The dysregulated lipid metabolism and the resulting
alterations in glucose homeostasis in Pref-1 transgenic
mice are attributable to the effects that Pref-1 has on the
adipose tissue development, which is the major target of
Pref-1 action. Our previous studies have unequivocally
demonstrated the critical role of Pref-1 in repressing
preadipocyte differentiation into adipocytes (14,17,38). In
vivo, repression of adipocyte differentiation by Pref-1 is
manifested by reduced expression of mature adipocyte
markers in WAT (19), including C/EBP, aFABP, or SCD,
and the consequent reduction in the ability to store
triglycerides and to secrete adipokines such as leptin and
adiponectin (Fig. 2 and Table 1). The reduction in fat mass
associated with high circulating levels of Pref-1 is not
constrained only to our transgenic model, but naturally
occurring mutations that affect the expression of Pref-1
result in a similar phenotype in other species. Indeed, in
sheep, a mutation of the intergenic region of chromosome
18 located between genes encoding for Pref-1—also
known as dlk1 (39)—and the noncoding gene Gtl2 in-
creases the expression of the Pref-1/dlk1 gene. The muta-
tion results in the callipyge phenotype, which is
characterized by pronounced muscle hypertrophy and
reduction of fat mass (40,41). Also, in pigs, a polymor-
phism in the Pref-1/dlk1 gene resulting in increased Pref-1
expression causes a decrease in fat deposition as well as
an increase in lean muscle mass (42). Although we have
not observed muscle hypertrophy in Pref-1 transgenic
mice, our studies clearly suggest that the decreased fat
mass observed in these models could be due to the
inhibitory effect of Pref-1 on adipocyte differentiation.
Similar phenotype, although more severe, has been ob-
served in different rodent models for total or partial
lipodystrophy, including PPAR
2-KO (43), conditional
PPAR

ldi KO (44), FAT-ATTAC mouse (45), aP2-DTA
mouse (46,47), aP2-nSREBP-1c (48), and aP2 A-ZIP/F1
fatless (49). These rodent models underscore the role of
adipose tissue as an integrator and critical regulator of
energy and glucose homeostasis in the organism. Most
of these genetically engineered mice are good models for
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2 KO and aP2-nSREBP-1c constitute acceptable
models for partial lipodystrophy. The analogy between
Pref-1 transgenic mice and the rodent models that are
totally or partially devoid of adipose tissue allows us to
propose Pref-1 transgenic mice as a new additional model
for partial lipodystrophy.
In humans, a strong correlation between the severity of
insulin resistance and the extent of loss of adipose tissue
has also been observed. So far, few genes responsible for
human lipodystrophies have been identiﬁed. These include
BSCL2/seipin and AGPAT2, which are associated with the
development of generalized lipodystrophy, as well as
lamin A/C and PPAR, which have been found to cause
partial lipodystrophy. Yet, no direct association has been
established between the expression of dlk1, the human
homolog of Pref-1, and the appearance of congenital
lipodystrophies. Interestingly, Pref-1 expression is in-
creased in adipose tissue of HIV-1–infected patients
that suffer from highly active antiretroviral treatment
(HAART)-associated lipodystrophy (50), a syndrome that
has a high incidence (between 25 and 50%) and is charac-
terized not only by wasting of subcutaneous fat, but also
by hyperlipidemia and insulin resistance (51). Although
the possible implication of Pref-1/dlk1 in human lipodys-
trophic syndromes is very suggestive, further studies will
be necessary to ﬁrmly establish the function of Pref-1 on
the development of adipose tissue disorders in humans.
In conclusion, our present study shows that high circu-
lating levels of the soluble form of Pref-1 prevents high-fat
diet–induced obesity but exacerbates insulin resistance,
which is associated with accumulation of DAG and de-
creased insulin sensitivity in skeletal muscle and WAT.
Mice overexpressing Pref-1 exhibit all the characteristics
of other lipodystrophic models, including reduced adipose
tissue mass, dyslipidemia, and insulin resistance and
therefore could be considered as a model for the study of
partial lipodystrophies.
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